❭ Research by medical division ❭ Laboratory Medicine ❭ Dept. of Immunology ❭ Blood and Lymphoproliferative Diseases (Munthe) ❭ Current projects ❭
Page visits: 1
Scroll to top

Home Dept. of Immunology Blood and Lymphoproliferative Diseases (Munthe)

  • Group members
  • Publications
  • Current projects

Recent publications

Viermyr HK, Tonby K, Ponzi E, Trouillet-Assant S, Poissy J, Arribas JR, Dyon-Tafani V, Bouscambert-Duchamp M, Assoumou L, Halvorsen B, Tekin NB, Diallo A, De Gastines L, Munthe LA, Murphy SL, Ueland T, Michelsen AE, Lund-Johansen F, Aukrust P, Mootien J, Dervieux B, Zerbib Y, Richard JC, Prével R, Malvy D et al. (2024)
Safety of baricitinib in vaccinated patients with severe and critical COVID-19 sub study of the randomised Bari-SolidAct trial
EBioMedicine, 111, 105511
DOI 10.1016/j.ebiom.2024.105511, PubMed 39731852

Alirezaylavasani A, Egner IM, Dahl B, Chopra A, de Matos Kasahara T, Goll GL, Jahnsen J, Grødeland G, Vaage JT, Lund-Johansen F, Holter JC, Halvorsen B, Jørgensen KK, Munthe LA, Kared H (2024)
Deficient SARS-CoV-2 hybrid immunity during inflammatory bowel disease
Clin Immunol, 271, 110404
DOI 10.1016/j.clim.2024.110404, PubMed 39645159

Ørbo HS, de Matos Kasahara T, Wolf AS, Bjørlykke KH, Sexton J, Jyssum I, Tveter AT, Solum G, Kjønstad IF, Bhandari S, Christensen IE, Kvien TK, Lind A, Kared H, Jahnsen J, Haavardsholm EA, Munthe LA, Provan SA, Vaage JT, Mjaaland S, Syversen SW, Jørgensen KK, Grødeland G, Goll GL (2024)
Humoral and cellular responses to a fifth bivalent SARS-CoV-2 vaccine dose in patients with immune-mediated inflammatory diseases on tumour necrosis factor inhibitors: a prospective cohort study
Lancet Reg Health Eur, 48, 101121
DOI 10.1016/j.lanepe.2024.101121, PubMed 39624496



More publications

Oslo University Hospital is a part of Southern and Eastern Norway Regional Health Authority.

Webmaster for research pages: Trond Olav Berg

Cookie policy

Accessibility statement (in Norwegian)